Last updated: April 26, 2026
Who Supplies Ulipristal Acetate for Pharma Use?
Suppliers of ulipristal acetate (UPA) split into two practical buckets: (1) API manufacturers supplying active pharmaceutical ingredient, and (2) ingredient intermediates / chemical suppliers feeding API production chains. The only fully decision-grade way to identify the right upstream suppliers is through regulatory, inventory, and tender documentation, because UPA availability depends on site qualification, DMF/CEP coverage, and controlled-chemical compliance.
What counts as a “supplier” for ulipristal acetate?
For procurement and patent-aware sourcing, companies typically mean one of:
- API manufacturer (ulipristal acetate, DMF/CEP site, GMP release)
- CMO / contract manufacturer (API synthesis and/or formulation under license)
- Raw chemical / intermediate supplier (building blocks used in UPA routes)
API Supply: Which firms commercially supply ulipristal acetate?
Are API manufacturers public and verifiable from patent/regulatory records?
No complete, authoritative supplier list can be produced from the information available in this conversation alone. A correct supplier map requires current DMF/CEP holders, drug master file listings, and procurement-market evidence that is not provided here.
What can be used as a sourcing “control point”?
For high-integrity supplier identification, the control point is typically:
- Regulatory dossiers (DMF or CEP) tied to specific manufacturing sites
- Finished product label references listing manufacturer responsibilities
- GMP batch release suppliers for the specific dosage form (tablets versus API)
Commercial sourcing constraints that shape supplier eligibility
What constraints narrow the pool to real suppliers?
UPA supply is constrained by:
- GMP status at the specific site releasing ulipristal acetate (API or drug product)
- Regulatory dossier coverage (DMF/CEP) for the target market
- Controlled chemical and hazardous precursor handling for synthesis routes
- Scale and impurity profile control (genotoxic impurity management and spec compliance)
- Patent and lifecycle claims that can affect import and generic API eligibility
Supply-chain map: Where procurement usually finds ulipristal acetate
How do pharma buyers source UPA in practice?
Most buyers proceed through one of two channels:
- Direct API purchase from an API manufacturer with validated dossier coverage
- Route-managed supply via CMO that produces UPA under GMP and supplies API or directly supplies formulated product
What information is typically used to qualify a UPA supplier?
Qualification packages typically include:
- GMP certificate for the manufacturing site
- DMF/CEP letter of authorization (if applicable)
- COA and stability package per agreed specification
- Impurity profile and control strategy
- Lead-time and capacity commitments
Patent-aware supplier selection: why supplier lists can’t be generic
Even when multiple firms can make ulipristal acetate, business eligibility for procurement depends on:
- Freedom-to-operate position for the buyer’s intended market and dosage form
- Whether a manufacturer’s site and dossier are legally permitted for the target jurisdiction
- Whether a supplier sells the same grade (API spec, impurity limits, polymorph form considerations where relevant)
Key Takeaways
- Ulipristal acetate sourcing should be treated as API-dossier-site procurement, not a generic “chemical supplier” purchase.
- A decision-grade supplier list requires DMF/CEP and GMP-site evidence tied to specific manufacturing responsibilities.
- Supplier eligibility for UPA is shaped by regulatory coverage, impurity specs, site GMP release, and patent constraints, which frequently reduce the usable supplier set to a small number of qualified sites.
FAQs
1) Can I buy ulipristal acetate from any chemical supplier?
Only suppliers with GMP-manufactured API and regulatory dossier coverage for your market should be used in pharma procurement.
2) Do suppliers differ by tablet versus API supply?
Yes. Some providers supply API only, while others operate as CMOs that supply intermediates, API, or finished tablets.
3) What documents should I expect in a real ulipristal acetate supply qualification package?
GMP certificate, COA, impurity profile/specs, stability data, and regulatory dossier linkage (DMF/CEP) for relevant jurisdictions.
4) Why do supplier lists online often conflict?
Because availability is tied to site qualification and dossier status, not just the ability to synthesize UPA.
5) Does patent status affect who can sell ulipristal acetate?
Yes. Patent and lifecycle claims can restrict legally compliant manufacturing or sales pathways for specific markets and dosage forms.
References
- (No sources were provided in the prompt; no verifiable supplier list can be compiled.)
